Liu Hanmeng, Shen Wei, Liu Wanguo, Yang Zexin, Yin Dengke, Xiao Chunsheng
School of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China.
Anhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei, Anhui, 230012, China.
Bioact Mater. 2023 Aug 14;31:206-230. doi: 10.1016/j.bioactmat.2023.08.007. eCollection 2024 Jan.
Traditional cancer therapy methods, especially those directed against specific intracellular targets or signaling pathways, are not powerful enough to overcome tumor heterogeneity and therapeutic resistance. Oncolytic peptides that can induce membrane lysis-mediated cancer cell death and subsequent anticancer immune responses, has provided a new paradigm for cancer therapy. However, the clinical application of oncolytic peptides is always limited by some factors such as unsatisfactory bio-distribution, poor stability, and off-target toxicity. To overcome these limitations, oncolytic polymers stand out as prospective therapeutic materials owing to their high stability, chemical versatility, and scalable production capacity, which has the potential to drive a revolution in cancer treatment. This review provides an overview of the mechanism and structure-activity relationship of oncolytic peptides. Then the oncolytic peptides-mediated combination therapy and the nano-delivery strategies for oncolytic peptides are summarized. Emphatically, the current research progress of oncolytic polymers has been highlighted. Lastly, the challenges and prospects in the development of oncolytic polymers are discussed.
传统的癌症治疗方法，尤其是那些针对特定细胞内靶点或信号通路的方法，在克服肿瘤异质性和治疗抗性方面不够强大。溶瘤肽能够诱导膜裂解介导的癌细胞死亡并引发后续的抗癌免疫反应，为癌症治疗提供了一种新的范例。然而，溶瘤肽的临床应用总是受到一些因素的限制，如生物分布不理想、稳定性差和脱靶毒性。为了克服这些限制，溶瘤聚合物因其高稳定性、化学多功能性和可扩展的生产能力而成为有前景的治疗材料，这有可能推动癌症治疗的一场革命。本文综述了溶瘤肽的作用机制和构效关系。然后总结了溶瘤肽介导的联合治疗以及溶瘤肽的纳米递送策略。重点突出了溶瘤聚合物的当前研究进展。最后，讨论了溶瘤聚合物开发中的挑战和前景。
